Find out about and locate Clinical Trials for Hepatitis

Paid Clinical Trials and Focus Groups


Find Paid Clinical Trials

Paid Clinical Trials - : Hepatitus

Top of Directory » All Categories » by Illness » Hepatitus



  • Safety and Efficacy of BMS-790052 Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)

    Condition:   Hepatitis C Infection
    Interventions:   Drug: BMS-790052;   Drug: BMS-790052;   Drug: Placebo;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
    Sponsor:   Bristol-Myers Squibb
    Not yet recruiting - verified November 2009
  • Safety and Efficacy of BMS-790052 Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2b and Ribavirin)

    Condition:   Hepatitis C Infection
    Interventions:   Drug: BMS-790052;   Drug: BMS-790052;   Drug: Placebo;   Drug: Peginterferon alfa-2b;   Drug: Ribavirin
    Sponsor:   Bristol-Myers Squibb
    Not yet recruiting - verified November 2009
  • Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

    Condition:   Chronic Hepatitis C
    Interventions:   Drug: BMS-790052;   Drug: BMS-650032;   Drug: pegylated-interferon-α;   Drug: ribavirin
    Sponsor:   Bristol-Myers Squibb
    Not yet recruiting - verified November 2009
  • An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys

    Condition:   Hepatitis B, Chronic
    Intervention:  
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • Study Comparing Reduction and Viral Safety of IFN Alfa-2b XL + Ribavirin Versus PEG IFN Alfa-2b + Ribavirin in Patients With Chronic Hepatitis C Genotype 1

    Condition:   Chronic Hepatitis C
    Interventions:   Drug: IFN alfa-2b XL 27 MUI + Ribavirin;   Drug: IFN alfa-2b XL 36 MUI + Ribavirin;   Drug: IFN peg alfa-2b 1.5 µg/kg + Ribavirin
    Sponsor:   French National Agency for Research on AIDS and Viral Hepatitis
    Not yet recruiting - verified November 2009
  • A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK7009

    Condition:   Hepatitis C
    Intervention:   Drug: MK7009
    Sponsor:   Merck
    Recruiting - verified November 2009
  • Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma

    Conditions:   Hepatocellular Carcinoma;   Hepatitis C Virus Chronic Infection
    Intervention:   Biological: CP 675,206
    Sponsors:   Instituto Cientifico y Tecnologico de Navarra, Universidad de Navarra;   Pfizer
    Recruiting - verified November 2009
  • Baclofen to Reduce Alcohol Use in Veterans With HCV

    Conditions:   Hepatitis C;   Alcohol Use Disorders
    Interventions:   Drug: baclofen;   Drug: placebo
    Sponsor:   Department of Veterans Affairs
    Not yet recruiting - verified November 2009
  • Human Anaplasmosis in Eastern France

    Conditions:   Anaplasmosis;   Tick-Borne Disease;   Ehrlichia
    Intervention:   Procedure: Blood sampling
    Sponsor:   University Hospital, Strasbourg, France
    Not yet recruiting - verified November 2009
  • The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise

    Conditions:   Herpesvirus;   Adenovirus;   Cytomegalovirus;   Human Papillomavirus;   Human Polyomavirus;   Respiratory Viruses
    Intervention:  
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified October 2009
  • Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine

    Condition:   Hepatitis, Chronic
    Interventions:   Drug: Lamivudine;   Drug: Telbivudine
    Sponsor:   University Hospital, Basel, Switzerland
    Recruiting - verified October 2009
  • Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4

    Conditions:   Liver Cirrhosis;   Hepatitis C Virus;   HIV Infection
    Intervention:   Drug: Pegylated interferon alfa-2a and Ribavirin
    Sponsor:   Sociedad Andaluza de Enfermedades Infecciosas
    Recruiting - verified October 2009
  • Safety, Immunogenicity, Lot-to-lot Consistency Study of the HBV Vaccine, HEPLISAV Compared to Engerix-B Vaccine

    Condition:   Healthy
    Intervention:   Biological: HEPLISAV
    Sponsor:   Dynavax Technologies Corporation
    Not yet recruiting - verified October 2009
  • Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection

    Condition:   Chronic Hepatitis C Virus Infection
    Interventions:   Drug: PEG-rIL-29;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
    Sponsors:   ZymoGenetics;   Bristol-Myers Squibb
    Recruiting - verified October 2009
  • Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With TwinrixTM Adult

    Conditions:   Hepatitis A;   Hepatitis B
    Interventions:   Procedure: Blood sampling;   Biological: Havrix;   Biological: EngerixTM-B
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009
  • Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer

    Condition:   Liver Cancer
    Interventions:   Drug: everolimus;   Drug: sorafenib tosylate;   Other: questionnaire administration;   Procedure: quality-of-life assessment
    Sponsor:   Swiss Group for Clinical Cancer Research
    Not yet recruiting - verified November 2009
  • ADHEPTA Study: Adherence Questionnaire in Hepatitis C

    Conditions:   Hepatitis C, Chronic;   HIV Infection
    Intervention:   Other: Adherence questionnaire
    Sponsor:   IMS Health
    Recruiting - verified October 2009
  • Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects

    Condition:   Hepatitis C
    Interventions:   Drug: Midazolam;   Drug: BMS-791325
    Sponsor:   Bristol-Myers Squibb
    Not yet recruiting - verified November 2009
  • Adding Nitazoxanide to Treatment for People With Hepatitis C Virus and HIV Coinfection

    Conditions:   HIV Infections;   Hepatitis C Virus
    Interventions:   Drug: Nitazoxanide (NTZ);   Drug: Peginterferon alfa-2a (PEG-INF);   Drug: Ribavirin (RBV)
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Not yet recruiting - verified October 2009
  • Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin

    Condition:   Chronic Hepatitis C Infection
    Intervention:   Drug: IDX184
    Sponsor:   Idenix Pharmaceuticals
    Not yet recruiting - verified October 2009
  • Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390

    Conditions:   Hepatitis C;   Thrombocytopaenia
    Intervention:   Drug: Eltrombopag
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009
  • Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

    Conditions:   Hepatitis;   Hepatitis C
    Interventions:   Drug: Filibuvir;   Drug: Filibuvir;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting - verified November 2009
  • Entecavir Plus Adefovir in Lamivudine-Resistant Patients

    Condition:   Hepatitis B, Chronic
    Interventions:   Drug: Lamivudine;   Drug: Entecavir;   Drug: Adefovir
    Sponsor:   Bristol-Myers Squibb
    Not yet recruiting - verified September 2009
  • Genotype Based Personalized Prescription of Nevirapine

    Conditions:   Nevirapine Induced Rash;   Nevirapine Induced Hepatitis;   HIV;   Adverse Side Effects;   AIDS;   HIV Infections
    Interventions:   Genetic: Genetic test for NVP induced rash;   Other: 3TC/D4T/NVP or 3TC/AZT/NVP
    Sponsors:   Mahidol University;   Ramathibodi Hospital;   Department of Medicine,Ramathibodi Hospital;   Chulalongkorn University;   Bamrasnaradura Institute, Ministry of Public Health;   Thammasat University;   Department of Preventive Medicine,Srinakharinwirot University;   Chiang Rai Regional Hospital;   Maharaj Nakornratchasima Hospital;   Department of Internal Medicine,Sawanpracharak Hospital;   Department of Internal Medicine,Burirum Hospital;   Department of Internal Medicine,Nakornping Hospital;   National Institute of Health, Department of Medical Sciences;   Clinical Research Center,Ministry of Public Health;   RIKEN
    Recruiting - verified September 2009
  • Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination

    Condition:   Hepatitis B
    Intervention:   Biological: Engerix™-B Kinder
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009
  • Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

    Condition:   Chronic Hepatitis C Genotype-1 Relapse
    Interventions:   Drug: NIM811;   Drug: Placebo BID + SOC
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified November 2009
  • Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

    Conditions:   Hepatitis C;   HIV Infections
    Interventions:   Drug: telaprevir or matching placebo;   Drug: telaprevir or matching placebo;   Biological: peginterferon alfa-2a;   Drug: ribavirin
    Sponsors:   Vertex Pharmaceuticals Incorporated;   Tibotec Pharmaceutical Limited
    Recruiting - verified November 2009
  • Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects

    Condition:   Chronic Hepatitis C
    Interventions:   Drug: BMS-790052;   Drug: Ortho Tri-Cyclen®
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified November 2009
  • Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072

    Condition:   Hepatitis C
    Interventions:   Drug: ABT-072;   Drug: Placebo
    Sponsor:   Abbott
    Recruiting - verified October 2009
  • The Raltegravir and Ribavirin Pharmacokinetics (PK) Study

    Condition:   HIV Infections
    Interventions:   Drug: Ribavirin;   Drug: Raltegravir
    Sponsor:   Imperial College London
    Recruiting - verified November 2009
  • TMC435-TiDP16-C206: A Safety and Efficacy Study in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

    Condition:   Hepatitis C
    Interventions:   Drug: TMC435 placebo /Peg IFNa2A/Ribavirin;   Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo;   Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo;   Drug: TMC435 /Peg IFNa2A/Ribavirin;   Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo;   Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo;   Drug: TMC435 /Peg IFNa2A/Ribavirin
    Sponsor:   Tibotec Pharmaceuticals, Ireland
    Recruiting - verified November 2009
  • A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia

    Condition:   Dyslipidemia
    Interventions:   Drug: anacetrapib;   Drug: Comparator: atorvastatin;   Drug: Comparator: Placebo
    Sponsor:   Merck
    Recruiting - verified November 2009
  • VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

    Condition:   Hepatitis C
    Intervention:   Drug: Telaprevir; Moxifloxacin; Placebo
    Sponsors:   Tibotec Pharmaceuticals, Ireland;   Vertex Pharmaceuticals Inc.
    Recruiting - verified November 2009
  • Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease)

    Condition:   Acute On Chronic Hepatitis
    Interventions:   Device: Extracorporeal Liver Assist Device (ELAD);   Other: Standard of care
    Sponsor:   Vital Therapies, Inc.
    Recruiting - verified October 2009
  • Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

    Condition:   Chronic Hepatitis C
    Interventions:   Drug: BMS-824393;   Drug: BMS-824393;   Drug: BMS-824393;   Drug: BMS-824393;   Drug: BMS-824393
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified October 2009
  • A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both

    Condition:   Hepatitis B, Chronic
    Interventions:   Drug: peginterferon alfa-2a (40KD) [Pegasys];   Drug: tenofovir
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies

    Condition:   Hepatitis B, Chronic
    Intervention:   Drug: peginterferon alfa-2a (40KD) [PEGASYS]
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

    Condition:   Hepatitis C, Chronic
    Interventions:   Drug: RO5190591;   Drug: RO5190591;   Drug: RO5190591;   Drug: RO5190591;   Drug: Placebo;   Drug: Placebo;   Drug: Pegasys;   Drug: Copegus
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • Hepatic Pharmacokinetics and Hepatitis C Virus RNA Levels After Administration of MK7009

    Condition:   Chronic Hepatitis C Infection
    Intervention:   Drug: MK7009
    Sponsor:   Merck
    Not yet recruiting - verified October 2009
  • A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411AM1)

    Conditions:   HIV Infections;   Hepatitis C;   HCV Infection
    Interventions:   Drug: PEG2b plus ribavirin followed by placebo;   Drug: PEG2b plus ribavirin followed by boceprevir/PEG2b/ribavirin
    Sponsor:   Schering-Plough
    Not yet recruiting - verified November 2009
  • Japanese Bridging Study Conducted in the United States

    Condition:   Hepatitis C Virus
    Interventions:   Drug: BMS-791325;   Drug: BMS-791325;   Drug: BMS-791325;   Drug: BMS-791325;   Drug: BMS-791325;   Drug: BMS-791325;   Drug: Placebo;   Drug: Placebo;   Drug: Placebo;   Drug: Placebo
    Sponsor:   Bristol-Myers Squibb
    Not yet recruiting - verified November 2009
  • A Study of MK7009 in Patients With Chronic Hepatitis C Infection After Participation in Other MK7009 Studies

    Condition:   Chronic Hepatitis C Infection
    Interventions:   Drug: MK7009;   Drug: Comparator: Pegylated Interferon (Peg-IFN);   Drug: Comparator: Ribavirin (RBV)
    Sponsor:   Merck
    Recruiting - verified November 2009
  • Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C

    Conditions:   Hepatitis C;   Liver Transplantation
    Interventions:   Drug: cyclosporin (Neoral);   Drug: tacrolimus
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified October 2009
  • Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration

    Conditions:   HIV Infection;   HIV Infections
    Intervention:   Drug: maraviroc
    Sponsors:   French National Agency for Research on AIDS and Viral Hepatitis;   Pfizer
    Recruiting - verified November 2009
  • VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram

    Condition:   Hepatitis C
    Intervention:   Drug: Telaprevir; Escitalopram
    Sponsor:   Tibotec Pharmaceuticals, Ireland
    Not yet recruiting - verified October 2009
  • A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

    Condition:   Hepatitis B, Chronic
    Intervention:   Drug: peginterferon alfa-2a (40KD)[PEGASYS]
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C

    Condition:   Hepatitis C, Chronic
    Interventions:   Drug: peginterferon alfa-2a [PEGASYS];   Drug: ribavirin
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol)

    Condition:   Hepatitis C
    Intervention:   Drug: filibuvir + Oral Contraceptives
    Sponsor:   Pfizer
    Not yet recruiting - verified November 2009
  • TMC435-TiDP16-C110: Evaluation of the (Possible) Influence of TMC435 on the Blood Levels of Methadone (and the Other Way Around), When TMC435 is Being Co-administerd to Study Participants Who Are Currently Being Treated With a Stable Dose of Methadone as Maintenance Therapy.

    Conditions:   Hepatitis C;   Hepacivirus
    Intervention:   Drug: TMC435
    Sponsor:   Tibotec Pharmaceuticals, Ireland
    Not yet recruiting - verified November 2009
  • VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.

    Conditions:   Hepatitis C;   Kidney Diseases
    Intervention:   Drug: telaprevir
    Sponsor:   Tibotec Pharmaceuticals, Ireland
    Recruiting - verified November 2009
    • Menu
    Find Paid Clinical Trials